Tofacitinib as a promising treatment for refractory erythroderma-like Hailey–Hailey disease
This case indicates that tofacitinib may serve as a promising therapeutic option for refractory erythroderma-like HHD, particularly in cases linked to <i>ATP2C1</i> mutations.
Authors
- Huaye Bao
- Keyi Yu (ORCID: https://orcid.org/0009-0004-6471-6400)
- Xingang Wu (ORCID: https://orcid.org/0000-0003-3041-9868)
- Feilong An
Institutions
- Third People's Hospital of Hangzhou (CN)
- Institute of Dermatology (TH)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1080/09546634.2025.2493936
- Citations
- 1
- Primary Topic
- Genetic and rare skin diseases.
- Type
- article
- Field-Weighted Citation Impact
- 1.82